FREQUENTLY ASKED QUESTIONS
About the iBCI-CC
-
The iBCI-CC is a collaborative community, using the collaborative community model described by the U.S. Food and Drug Administration (FDA), focused on implantable brain-computer interfaces. We are a group of clinicians, researchers, industry representatives, ethicists, patient advocacy groups, individuals with lived experience, and care partners who collaborate to address shared challenges—including scientific, clinical, regulatory, and reimbursement challenges—related to implantable brain-computer interface (iBCI) technology. As iBCIs transition from research settings into early clinical use, the field faces common questions around safety, performance, clinical integration, and reimbursement that no single stakeholder can resolve alone. Our primary purpose is to support coordination across the field, promote best practices, foster collaboration, and address key challenges to advance the development, evaluation, clinical implementation, and access of safe and effective iBCIs. Please refer to our Charter for more information.
-
The iBCI-CC serves as a forum for dialogue with participants from regulatory and reimbursement bodies, including the U.S. Food and Drug Administration (FDA) and Centers for Medicare & Medicaid Services (CMS). The FDA has formally authorized a federal liaison to exchange information and views with our community, on behalf of the FDA. These conversations, per our Charter, occur in a pre-competitive space, allowing for transparent discussion amongst all stakeholders.
We facilitate discussions on safety and efficacy, explore coverage considerations, and develop evidence-based resources and shared approaches that may inform regulatory science, policy, and reimbursement discussions. Our initial regulatory and translational work is focused primarily on device use in the United States, while our membership includes international stakeholders and our work considers developments across the global field. To keep our forum open to federal employees, whose ability to lobby or engage in political speech is restricted (see: Hatch Act), the iBCI-CC abstains from legislative advocacy.
Participation by FDA, CMS, or other government bodies does not constitute endorsement of any specific iBCI technology, and the Collaborative Community does not replace formal regulatory, coverage, or reimbursement processes.
-
We actively include people with lived experience of neurologic disease or injury and their care partners in our workgroups and decision-making processes. We also collaborate with patient advocacy organizations to ensure our outputs reflect the expressed needs and priorities of current and future iBCI users.
-
You can get involved by filling out a membership application on our website or by emailing us at ibci.collab@gmail.com.
-
The best way to stay updated is by visiting our website, where we post regular updates, news, and information about our initiatives and workgroup progress. You can also find us on LinkedIn and YouTube. When you become a member, you will receive updates and notifications about the Workgroups you’re participating in.
About iBCI Technology
-
The iBCI-CC uses a specific definition of “implantable brain-computer interface” that helps set the scope of our activities, which can be found here. Under this definition, an implantable brain-computer interface (iBCI) is a system that creates a direct communication pathway between the brain and a computer or other external device. Electrodes are implanted under the scalp or skull to detect brain signals, which are then translated into commands to control devices like a computer cursor, robotic arm, or wheelchair. These systems interpret patterns of neural activity associated with a person’s intent to move or communicate, enabling interaction with external technologies. A broader definition of “BCI” is available at the BCI Society website.
-
Currently, iBCIs are being studied to help individuals with severe speech or motor impairments resulting from conditions such as amyotrophic lateral sclerosis (ALS), spinal cord injury, brainstem stroke, and other neurologic diseases or injuries. The technology has the potential to restore communication and control of assistive devices. iBCIs are also being developed to potentially help people with other disorders of the central or peripheral nervous system.
-
In clinical trials, participants who are unable to move or unable to speak have successfully used iBCIs to perform tasks such as typing messages, controlling a computer mouse, playing video games, operating robotic limbs, and using their intent to speak to generate text on a screen that is then made audible through a text-to-speech synthesizer. These initial applications show how neural signals associated with intended movement or intended speech can be used to interact with common digital tools and assistive technologies.
-
A primary difference is in how the sensors are placed. iBCIs use sensors that are implanted under the scalp or skull, which allows them to capture higher quality neural signals for complex tasks. Non-implantable BCIs use sensors temporarily placed on or near the scalp, similar to a headband or cap, and the signals they measure are generally less precise. The two approaches involve trade-offs. Non-implantable BCIs require no surgery and can be removed easily, though they generally provide lower signal quality and need to be set up and calibrated for each use. iBCIs require a surgical procedure and carry the associated risks, and in return they can offer higher-fidelity signals and the potential for continuous, independent use.
-
iBCI technology in the U.S. is still considered investigational, and clinical studies are conducted under applicable regulatory, institutional, and ethical oversight designed to protect research participants. At this time, some iBCIs are being evaluated in FDA-authorized investigational studies, with study-specific requirements for voluntary, rigorous informed consent, ongoing safety monitoring, and reporting. Each study is also overseen by an institutional review board and the research team. In current U.S. research, implantation occurs only within an authorized study following informed consent and applicable ethical and regulatory review. For more information about specific investigational devices, visit ClinicalTrials.gov.
The longest running iBCI clinical trial published results demonstrating an interim safety profile comparable to other chronically implanted medical devices. However, safety profiles can vary by device, study protocol, and patient population, and are evaluated on a case-by-case basis within clinical and research trials. For more information about specific investigational devices, visit ClinicalTrials.gov.
-
Risks are similar to other neurosurgical procedures of the brain and may include infection, stroke, seizure, bleeding, device malfunction, or the need for additional surgeries. There may also be long-term risks, such as tissue damage or signal deterioration over time. All clinical trials communicate risks associated with the specific device as part of the informed consent process for research. These risks are closely monitored under defined safety protocols. The iBCI-CC's Clinical Practice Guidelines Workgroup is working to develop frameworks to help mitigate these risks when iBCIs move beyond the research setting and into clinical practice.
-
iBCIs are currently in the research and clinical trial phase and are not yet commercially available in the U.S. While the goal is to bring this technology to market, a timeline depends on clinical trial outcomes, regulatory approvals, and establishing pathways for clinical use and health insurance reimbursement. Regulatory status and availability differ in other countries.
-
The longevity of iBCI devices is still being evaluated in clinical trials and varies by device design, component, and intended use. Some research implants have remained implanted and functional for many years, including over a decade, but the expected service life of future clinically available iBCI systems has not yet been established.
If a device or component of an investigational system fails, the participant and clinical or research team will assess the appropriate course of action in accordance with the study protocol and the participant’s circumstances. Depending on the device and the nature of the issue, this may include troubleshooting or replacing external components, continued monitoring, revision, replacement, or removal of the implant. Available options may also depend on regulatory requirements and the design of the specific study.
-
People who enroll in clinical research generally do not need to pay to receive an investigational iBCI, as this cost is covered by the research team, medical device company, or funding agency. Other associated costs associated with participation may vary by study. As iBCIs are investigational, specific costs for the to-be-approved medical devices have not been determined. It is also not yet known the extent to which insurance will cover the placement and support of these devices. The iBCI-CC's Payor Interactions and Device Categorization Workgroup is actively exploring pathways for future coverage and reimbursement.
-
While practice can improve performance, some users have been able to use an iBCI effectively from the first day.
-
Data collected through iBCI research are subject to protections that vary depending on the study, institution, type of data, and applicable laws and regulations. Data handling practices are defined within each study protocol and overseen by institutional review boards and research teams. Study materials should explain what data are collected, how and where they are stored, who may access them, how they may be used or shared, how long they may be retained, and what privacy and security safeguards apply. Additional legal, institutional, contractual, and cybersecurity requirements may also apply depending on the study and jurisdiction. The iBCI-CC's Ethics, Neural Data Privacy, and Data Security Workgroup is developing best practices for this area.
-
Compatibility with MRI and CT varies by device and by the specific components of the iBCI system. People participating in an iBCI study should inform both the study team and the imaging facility before undergoing either MRI or CT. MRI may be prohibited or permitted only under specific conditions, depending on the device. CT is often possible, but may require device-specific precautions and can produce imaging artifacts.
About Clinical Trials
-
Eligibility criteria vary by study but typically include individuals with severe neurological impairments. Candidates must meet specific medical criteria and be able to commit to the research activities required by the trial. Each study has its own inclusion and exclusion criteria designed to ensure participant safety and the integrity of the research. You can find eligibility criteria for specific studies at ClinicalTrials.gov.
-
Information on active iBCI clinical trials can be found on platforms like ClinicalTrials.gov. This database provides information reported for registered studies, including study locations, eligibility requirements, and contact information for research teams. Because recruitment status can change, interested individuals should confirm current availability directly with the study contact listed on ClinicalTrials.gov. You can also contact research institutions with expertise in clinical neurotechnology for information on recruiting studies.
-
To find and apply for iBCI clinical trials, you can visit ClinicalTrials.gov and search for terms like "brain-computer interface" or "neurotechnology." This will provide a list of registered trials and contact information. Interested individuals can reach out directly to the study contacts listed to learn more about participation and screening procedures. Eligibility is determined by each study’s specific inclusion and exclusion criteria, and contacting a study does not guarantee enrollment.